Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy

ESMO Gastrointestinal Oncology · Elsevier

Аннотация

Publication date: December 2026 Source: ESMO Gastrointestinal Oncology, Volume 14 Author(s): J.W. Lee, P.E. Oberstein, J.D. Goldberg, M. Jia, D. Becker, D. Siolas, N. Beri, T. Ryan, P. Kozuch, B. Levinson, L.P. Leichman, D.J. Cohen

Читать у издателя →

Похожие статьи